NCT06930755招募中1 期
Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer
Nerviano Medical Sciences6 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2026年5月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 6
- 主要终点
- Number of Participants with Adverse Events (AEs)
研究概览
简要总结
This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of high-grade serous epithelial ovarian, fallopian tube or peritoneal cancer. Sponsor might opt to restrict enrollment to either platinum refractory, primary or secondary platinum-resistant patients based on data emerging from the trial.
- •Patients must have received no more than 5 prior lines of therapy and failed all evidence based local standards of care as per Investigator judgment. Sponsor might opt to restrict prior lines of therapy to 3 in any moments, based on data emerging from the trial.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Patient must have progressed radiographically on or after their most recent line of anticancer therapy and have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (radiologically measured by the Investigator).
- •Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0) Grade ≤ 1 or to the baseline laboratory values as defined in the protocol
- •Patients with childbearing potential must use highly effective contraception or true abstinence.
排除标准
- •Current enrollment in another interventional clinical trial.
- •Current treatment with other anticancer agents or devices.
- •BReast CAncer gene (BRCA) mutation.
- •Prior therapy with PARP inhibitor, outside of approved indication and schedules. Sponsor might opt to restrict prior use of PARP inhibitor (PARPi) in any moments, based on data emerging from the trial.
- •Prior therapy with topoisomerase inhibitors including payloads of Antibody-Drug Conjugates (ADCs). Sponsor has the option to allow prior ADC, if not last line of treatment, prior to enrollment.
- •Major surgery, other than surgery for recurrent Ovarian Cancer (OC), within 4 weeks prior to treatment start.
- •Patients with low-grade/borderline ovarian tumor.
- •Prior anti-tumor treatment within 2 weeks prior to treatment start or 5 half-lives, whichever is shorter.
- •Patients with prior wide-field radiotherapy (RT) affecting at least 20 percent of the bone marrow.
- •Use of full-dose anticoagulants unless the INR or activated thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least 2 weeks before enrollment.
- •Treatment with concomitant medications known to be sensitive substrates of CYP2D6 and CYP2C19 that cannot be replaced with another treatment.
- •History of interstitial lung disease or relevant lung disease in the opinion of the Investigator.
- •Treatment with systemic immune modulators such as corticosteroids at prednisone equivalent dose of > 10 mg/day, cyclosporine and tacrolimus or radiotherapy within 28 days before Cycle 1 Day
- •Pregnant women. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within the screening period prior to start of study drug.
- •Breast-feeding women or women planning to breast feed during the study or within 3 months after study treatment.
- •Known hypersensitivity to any component of NMS-03305293 or topotecan drug formulations.
- •Known active, life-threatening or clinically significant uncontrolled systemic infection (bacterial, fungal, viral including Human Immunodeficiency Virus (HIV) positivity or Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infections) requiring systemic treatment; HIV or AIDS-related illness are allowed as long as controlled more than 6 months to undetectable on anti-HIV medications.
- •Patients with QTc interval ≥ 450 milliseconds or with risk factors for torsade de pointes (e.g., uncontrolled heart failure, uncontrolled hypokalemia, history of prolonged QTc interval or family history of long QT syndrome). For patients receiving treatment with concomitant medications known to prolong the QTc interval, replacement with another treatment prior to enrollment is mandatory. If concomitant use of anti-emetics is considered essential for the care of the patients, follow instruction in this protocol.
- •Known active gastrointestinal disease (e.g., documented gastrointestinal ulcer, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes or structural issues or ulcer that would impact on drug absorption.
- •Any of the following in the previous 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, active bleeding disorder and interstitial lung disease.
- •History of long QT disorder or familial sudden death syndromes or related syndromes in the opinion of the Investigator.
- •Currently active second malignancy, except for adequately treated basal or squamous cell skin cancer and/or cone biopsied or post curative intention in situ carcinoma of the cervix uteri and/or superficial bladder cancer.
- •Symptomatic, or untreated Central Nervous System (CNS) lesions except stable and well-controlled with no neurological symptoms; patients receiving corticosteroids to control neurological symptoms should be on stable doses for at least 14 days before study entry.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
- •NOTE: Other protocol defined inclusion and exclusion criteria may apply.
研究组 & 干预措施
NMS-03305293 and Topotecan
Experimental
NMS-03305293 will be administered orally, twice daily, on a 1-7-day schedule, in repeated 4-week cycles (i.e., 28 days). Topotecan will be administered intravenously (IV), once weekly, on Days 1, 8, and 15, of Weeks 1-3, in repeated 4-week cycles (i.e., 28 days) at 4 mg/m^2 with maximum dose of 4 mg.
干预措施: Topotecan (Drug)
NMS-03305293 and Topotecan
Experimental
NMS-03305293 will be administered orally, twice daily, on a 1-7-day schedule, in repeated 4-week cycles (i.e., 28 days). Topotecan will be administered intravenously (IV), once weekly, on Days 1, 8, and 15, of Weeks 1-3, in repeated 4-week cycles (i.e., 28 days) at 4 mg/m^2 with maximum dose of 4 mg.
干预措施: NMS-03305293 (Drug)
结局指标
主要结局
Number of Participants with Adverse Events (AEs)
时间窗: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 6 months)
Evaluation of type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version 5.0), duration of AEs, first cycle DLT, electrocardiogram (ECG) and laboratory abnormalities and relationship of AE to study treatment
Number of Participants with Adverse Events (AEs)
时间窗: Screening (Day ≤28) up to 28-day follow-up after end of treatment (Approximately 6 months)
Evaluation of type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version 5.0), duration of AEs, first cycle DLT, electrocardiogram (ECG) and laboratory abnormalities and relationship of AE to study treatment
次要结局
- Overall Response Rate (ORR)(From the date of first response up to data cut-off (approximately 22 months))
- Duration of response (DoR)(From the date of first response up to data cut-off (approximately 22 months))
- Progression-free survival (PFS)(From the date of treatment initiation up to data cut-off (approximately 24 months))
- Overall survival (OS)(From the date of treatment initiation up to data cut-off (approximately 24 months))
- Overall Response Rate (ORR)(From the date of first response up to data cut-off (approximately 22 months))
- Duration of response (DoR)(From the date of first response up to data cut-off (approximately 22 months))
- Overall survival (OS)(From the date of treatment initiation up to data cut-off (approximately 24 months))
- Progression-free survival (PFS)(From the date of treatment initiation up to data cut-off (approximately 24 months))
- Plasma pharmacokinetic profile of NMS-03305293 and possible identified metabolites (if appropriate) after oral administration(Cycle 1 - Days 1, 2, and 5. Each cycle is 28 days)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
1 期
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent GlioblastomaDiffuse GliomaGlioblastomaNCT04910022Nerviano Medical Sciences150
已完成
1 期
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.Small Cell Lung CarcinomaNCT04358237Antonio Calles Blanco28
招募中
1 期
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent GlioblastomaMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2Recurrent GlioblastomaCTIS2023-508318-41-00erviano Medical Sciences S.r.l.75
招募中
2 期
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent GlioblastomaDiffuse Glioma10027655GlioblastomaNL-OMON56287erviano Medical Sciences Srl, Italy16
进行中（未招募）
1 期
A study of experimental drug NMS-03305293 in combination with temozolomide in adult patients with a type of brain tumour called glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)GlioblastomaEUCTR2020-003417-35-NLerviano Medical Sciences S.r.l75